Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
17.01. | Meet the Company Developing an At-Home Test to Replace the Pap Smear | ||
16.01. | Pfizer CEO At JPM Issues Clear Warning to Kennedy on Vaccines | ||
16.01. | Form Health Unveils New Program to Prevent the Transition from Overweight to Obesity | ||
16.01. | From Paper Charts to AI Scribes: The EHR Revolution | ||
16.01. | The Near-Term Future of AI in Health Care | ||
16.01. | Providence Spun Out Its VC Arm So It Can Partner with Other Health Systems | ||
16.01. | Healthcare Leaders Support FTC's Second Report on PBMs, While PBMs Criticize Findings | ||
15.01. | Tech-driven Heart Care Key to Cardiology Desert Crisis | ||
15.01. | Is 'Big Data' the Cure-all for U.S. Healthcare? | ||
15.01. | GVX Venture Studio Launches FusionCare.AI: A One-Stop Shop for Obesity Care at the Future and Health Executive Summit at JPM 2025 | ||
15.01. | At JPM, Eli Lilly's CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected | ||
15.01. | Is Medtronic On the Cusp of Rewriting the Story of Renal Denervation? | ||
15.01. | Qventus Snags $105M for Its Patient Flow Automation Tech | ||
14.01. | Solera Health Raises $40M Series E Round Co-Led by Health Care Service Corporation | ||
14.01. | A Strategic Growth Plan for Primary Care Practices | ||
14.01. | How Developers Can Use Patient Feedback to Improve Health Outcomes | ||
14.01. | 2025 Trends in Health IT | ||
14.01. | Improving the Healthcare Financial Experience to Help Care Flow | ||
14.01. | One Healthcare AI Application that Intrigues Intermountain Health's CEO | ||
14.01. | J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies | ||
14.01. | Nvidia Announces Partnerships with Mayo Clinic, Illumina & More at JPM25 | ||
14.01. | Rock Health: Digital Health Funding Drops in 2024, Investors Shift Focus to Early-Stage Startups | ||
13.01. | Prioritize Provider Data for Seamless M&A Success | ||
13.01. | AI, IP and Your Healthcare: And You Thought the Doctor's Exam Was Intrusive! | ||
13.01. | Gilead's New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target |